Zelboraf
(vemurafenib)Phase 3Small molecule
Vemurafenib is used to treat certain types of melanoma (a serious skin cancer) and other cancers that have a specific genetic mutation called BRAF V600E. It works by blocking the cancer cells' ability to grow and spread.[1] Zelboraf is currently being investigated across 20 indications[3], with its most advanced program in Phase 3.[1]
Zelboraf is one of 523 small molecule programs targeting Glioma. It is currently in Phase 3.
20
Indications
131
Total Trials
30
Active Trials
522
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
6
Patents
Pipeline
Status by Indication[3][1]
Indication
Showing 10 of 20 indications
Competition
Competitive Landscape
1774 competitors in Lymphoma
#DrugCompanyPhaseTrials
1Zelboraf
CConrado Roberto Hoffmann Filho
Phase 3
Velban
EEastern Cooperative Oncology Group
Preclinical
Oncaspar
SServier
Preclinical
Zofran
NovartisPreclinical
Norvir
AbbViePreclinical
Wellcovorin
GGlaxo Dba Glaxosmithkline
Preclinical
Tafasitamab
IncytePreclinical
Elitek
AAzienda U.S.L. 1 di Massa e Carrara
Preclinical
PEG-Intron
Merck & Co.Preclinical
Rhg-CSF
CCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Melanoma39 trials
Show 36 more trials
LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma
Completed·—·Phase 1/2·NCT03101254·5 enrolled
A Phase I Trial of Vemurafenib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma
Completed·—·Phase 1·NCT01897116·8 enrolled
XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma
Active, not recruiting·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT02721459·26 enrolled
Metastatic Melanoma21 trials
Show 18 more trials
A Pilot Study of Trientine With Vemurafenib for the Treatment BRAF Mutated Metastatic Melanoma
Withdrawn·—·Phase 1·NCT02068079
Thyroid Cancer6 trials
Treatment5 trials
Metastatic Colorectal Cancer5 trials
43 more indications
BRAF V600 Mutation3 trials
Trial3 trials
Hairy Cell Leukemia3 trials
Metastatic2 trials
Tics2 trials
Malignancies2 trials
Non-Small Cell Lung Cancer2 trials
Tic Disorder2 trials
Immunotherapy1 trial
Advanced Solid Tumors1 trial
Advanced Stage Cancer1 trial
Clinical Trial1 trial
Induction Therapy1 trial
Glioma1 trial
Advanced Cancer1 trial
Lymphoma1 trial
Colorectal Cancer1 trial
Craniopharyngioma1 trial
Various Advanced Cancer1 trial
Hepatic Impairment1 trial
Genomic Alterations1 trial
Pilot Study1 trial
Relapsed or Refractory1 trial
Advanced Solid Malignancies1 trial
Patients With Solid Tumors1 trial
Rare Tumor1 trial
PLATFORM Study of Precision Medicine for Rare Tumors
Recruiting·—·Phase 2·NCT04423185·770 enrolled
BRAF V600E Mutation1 trial
A Combination of Vemurafenib, Cytarabine and 2-chlorodeoxyadenosine in Children With LCH and BRAF V600E Mutation
Unknown status·FFederal Research Institute of Pediatric Hematology, Oncology and Immunology·Phase 2·NCT03585686·12 enrolled
Sarcoma1 trial
Advanced Malignancies1 trial
Cutaneous Melanoma1 trial
Differentiated Thyroid Carcinoma1 trial
Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation
Recruiting·—·Phase 2·NCT06440850·21 enrolled
Histiocytosis1 trial
Haematological Malignancy1 trial
Solid Tumor1 trial
Regulatory
FDA Approval Timeline[4]
Aug 17, 2011
ZELBORAF
NDA NDA202429
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for vemurafenib. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
- [6]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Serine/threonine-Protein Kinase B-RAF Inhibitor[2]
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- CConrado Roberto Hoffmann Filho